|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Novartis AG (NYSE: NVS), a developer and manufacturer of pharmaceuticals and nutritional products. |
|---|---|
| Transferring Party | Alcon Inc. (NYSE: ACL), a maker of surgical equipment, implantable lenses, and other eye care products. |
| Sector | Medical Devices |
| Date | April 7, 2008 |
| Analysis A two-stage deal to buy Nestlé's 77% stake in Alcon. The world's largest eye care company with sales of $5.6b, Alcon complements Novartis's own $2.5b contact lens unit Ciba Vision. Novartis bought a 25% stake in Alcon for $10.4b and has the right to buy Nestle's remaining 52% stake for about $28b in 2010 or 2010. Total deal value (including remaining 52% not owned by Novartis or Nestle) ~ $38b on sales of $5.6b and EBITDA - $2.1b. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |